[1]

QI Linling, LIU Shourong. Research progress of tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 578-582.

[2]

TAO Chengjing, LIU Shourong, CHENG Xiaoxian, HU Jiannv, BAI Xiuli, ZHANG Suying, ZHAO Chun, ZUO Zhongbao. Effects of different postpartum withdrawal time of tenofovir on hepatitis B virus markers, virology and biochemical indexes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1146-1152.

[3]

CHEN Yonghua, CAO Qunfen, HONG Qiongyi, WANG Shumin. Effect of tenofovir disoproxil fumarate on serum FGF-23，β2-MG，Cys-C and RBP level in patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 799-804.

[4]

LUAN Ling, ZHANG Jing-Liang. Clinical efficacy of atomolan in treatment of the patients with virus hepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 351-353.

[5]

ZHANG Jing-Liang, JIA Chuan-Chun, LUAN Ling. Comparison of the efficacy between stronger Neo-Minophagen C(SNMC) and caryophyllin in treatment of patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 207-209.

[6]

YU Yong-Sheng, CHEN You-Hua. Recent advances in genetic therapy for anti-hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 574-576.

[7]

LI Yi-Ling, WANG Feng-Ha, LI Qing-Yang. Effets of interferon α-2b on serum hpaluronic acid in patients with hypatitis B and hypatitis C [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 80-80.

[8]

. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 370-370.

[9]

. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(3): 247-247.

[10]

YU Yong-Sheng, CHEN You-Hua. Immune modulation of anti-HBV iRNA from different sources in patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(3): 210-212.

[11]

. [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(3): 231-232.

[12]

WANG Chun-Ge, ZHANG Yi. Therapeutic progress on the treatment of hepatitis B recurrence after liver transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(3): 283-285.

[13]

PENG Guan-qing, ZHANG Chang, LIU Xue-feng. Clinical character of patients relapsed after withdrawal with lamivudine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1166-1169.

[14]

LIU Xue-ni, PAN Qing-chun, ZANG Guo-qing, YU Yong-sheng. Structure of hepatitis B virus core protein and disablement in the hepatitis B antiviral therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1170-1173.

[15]

ZHU Yue-ke, DUAN Zhong-ping, WANG Bao-en, SHAN Jing, CHEN Yu, HAN Da-kang, ZHAO Jun. Therapeutic effects of silybin-phosphatidylcholine compound on patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1392-1394.

PDF (PC)

Knowledge